Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 14, 503-507
Abstract
Background: Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus after taking a dolutegravir (DTG)-based ART regimen. Case Presentation: HIV-infected patients who had been on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimens for more than a decade were shifted to integrase strand transfer inhibitors (dolutegravir)-based ART regimen as recommended by the National Comprehensive HIV Care Guideline. They were diagnosed to have diabetes mellitus with or without diabetic ketoacidosis (DKA) as evidenced by polyuria, polydipsia and fatigue, severe hyperglycemia (plasma glucose level > 250 mg/dl) with or without ketonuria (3+) after 1– 12 months of DTG-based ART regimen. Two of the patients who presented with DKA were treated with intravenous fluids and regular insulin. NPH insulin was started following recovery from DKA, which later shifted to metformin. One of the patients who presented with severe hyperglycemia without DKA was started with NPH insulin, which later shifted to metformin. Good glycemic control was obtained with metformin, while the DTG-based ART regimen was continued. Conclusion: Hyperglycemia is a potential and noticed side effect of the DTG-based ART regimen. Baseline and periodic monitoring of plasma glucose might be required in ART regimens containing dolutegravir.Keywords
This publication has 14 references indexed in Scilit:
- Update on Adverse Effects of HIV Integrase InhibitorsCurrent Treatment Options in Infectious Diseases, 2019
- 345. Acute Onset Diabetic Ketoacidosis/Hyperosmolar Hyperglycemic State in Patients Taking Integrase Strand Transfer InhibitorsOpen Forum Infectious Diseases, 2019
- SUN-187 Dolutegravir Causing DiabetesJournal of the Endocrine Society, 2019
- Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyThe Lancet HIV, 2019
- Dolutegravir-induced hyperglycaemia in a patient living with HIVJournal of Antimicrobial Chemotherapy, 2017
- Integrase strand transfer inhibitor-associated diabetes mellitus: A case reportInternational Journal of STD & AIDS, 2016
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyThe Journal of Infectious Diseases, 2014
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyThe Lancet, 2013